Daily Market Commentary for February 25, 2014

Bristol-Myers Squibb Company (BMY) received approval from the U.S. Food and Drug Administration on February 24 for Myalept (metreleptin for injection) as replacement therapy to treat the complications of leptin deficiency in patients with congenital generalized or acquired generalized lipodystrophy.

read more at:http://www.millennium-traders.com/news/newscommentary.aspx


Thanks for reading
Millennium-Traders.Com
http://www.millennium-traders.com